EP Patent

EP1906916B1 — Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders

Assigned to Alcon Inc · Expires 2008-10-29 · 18y expired

What this patent protects

Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamine nonionic surfactant and a glycol tonicity-adjusting agent such as propylene glycol.

USPTO Abstract

Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamine nonionic surfactant and a glycol tonicity-adjusting agent such as propylene glycol.

Drugs covered by this patent

Patent Metadata

Patent number
EP1906916B1
Jurisdiction
EP
Classification
—
Expires
2008-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Alcon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.